Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance

Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.